Articles

ST.26 Sequence Listing Format: Complete Migration Guide for 2026

If you are a patent professional, bioinformatics specialist, or IP attorney dealing with nucleotide or amino acid sequences, then the st.26 sequence listing migration is the most critical compliance shift you need to understand right now. The World Intellectual Property Organization (WIPO) officially replaced the old ST.25 standard with ST.26, and as of January 1, 2022, all patent applications involving biological sequences must follow this new format. However, many applicants are still catching up, making 2026 a pivotal year for full global compliance.

This guide is designed to walk you through everything in plain, practical language so that you know exactly what to do, why it matters, and how to avoid costly mistakes.

What Is ST.26 and Why Does It Matter?

ST.26 is the new WIPO standard for disclosing nucleotide and amino acid sequences in patent applications. It replaces the older ST.25 standard, which had been in use since the 1990s. The core difference is the file format. ST.25 used a plain text format, while ST.26 uses XML (eXtensible Markup Language), which is machine-readable, structured, and far more compatible with modern bioinformatics databases.

The shift to ST.26 sequence listing migration is not just a formatting update. It is a fundamental change in how biological sequence data is submitted, validated, and processed by patent offices worldwide. Every major patent office, including the USPTO, EPO, JPO, and WIPO itself, now mandates ST.26-compliant XML files for new applications.

If your organization is still using ST.25 format or has pending applications in the pipeline that have not been updated, 2026 is the year to complete that transition without exception.

Key Differences Between ST.25 and ST.26

Understanding the differences is the foundation of any successful st.26 sequence listing migration. Here is what changed at a technical and practical level:

File Format ST.25 used a .txt file with a proprietary WIPO format. ST.26 uses a strictly defined XML schema (.xml), which follows the WIPO ST.26 XML DTD (Document Type Definition).

Sequence Coverage ST.25 covered DNA, RNA, and protein sequences. ST.26 expands coverage to include d-amino acids, modified bases, and other non-standard residues that are increasingly common in modern biotech and pharmaceutical patent filings.

Language and Character Sets ST.26 supports Unicode, which means applicants can include sequence names, organism names, and feature annotations in multiple languages, a significant improvement for international filings.

Feature Annotations In ST.25, feature annotations were relatively loose and inconsistently applied. ST.26 enforces strict use of controlled vocabulary from resources like the Feature Table Documentation, ensuring consistency across all filings globally.

Validation ST.26 files must be validated using WIPO’s official WIPO Sequence software before submission. ST.25 had no mandatory pre-submission validation tool.

Step-by-Step ST.26 Sequence Listing Migration Process

The actual st.26 sequence listing migration process can feel overwhelming, but breaking it into clear steps makes it manageable. Whether you are converting legacy ST.25 files or creating new ST.26 listings from scratch, follow this structured approach.

Step 1: Audit Your Existing Sequence Data – Begin by cataloguing all existing sequence listings in your patent portfolio. Identify which applications are already filed under ST.25, which are pending, and which are new filings. This audit will define the scope of your migration work.
Step 2: Download and Install WIPO Sequence Software – WIPO provides a free, official tool called “WIPO Sequence” that supports both the creation and validation of ST.26 XML files. It also includes a conversion feature for importing ST.25 .txt files and converting them to ST.26 format. Always use the latest version available on the WIPO website.
Step 3: Convert or Create Sequence Listings – For existing ST.25 files, use the import/conversion feature in WIPO Sequence. For new applications, enter sequence data directly into the tool. Be especially careful with non-standard residues, modified amino acids, and sequence annotations, as these require manual review during the st.26 sequence listing migration process.
Step 4: Validate Before Submission – This is non-negotiable. Run every XML file through the WIPO Sequence validator. Common validation errors include incorrect feature keys, missing mandatory fields like organism name, and improperly formatted qualifiers. Fix all errors before submission.
Step 5: Coordinate with Local Patent Counsel – Requirements can vary slightly between patent offices. The USPTO, EPO, and other offices may have additional local rules regarding ST.26 file naming, size limits, or submission portals. Always confirm requirements with local counsel or directly on the patent office website.

Common Mistakes to Avoid During Migration

Even experienced patent professionals make errors during the st.26 sequence listing migration. Being aware of these pitfalls saves time and prevents rejection.

Many applicants incorrectly assume that automatic ST.25 to ST.26 conversion produces a perfect file. It does not. The conversion tool does a good job, but manual review is essential, particularly for sequences containing ambiguous residues or complex feature tables.

Another frequent issue is inconsistent organism naming. ST.26 requires organism names to match recognized taxonomic nomenclature. If your ST.25 file used informal or abbreviated organism names, these need to be corrected to the full scientific name during migration.

Some applicants also overlook the requirement to include a separate ST.26 XML file even when the sequence data is embedded within the main patent body. Every application with five or more sequences, or even a single sequence of ten or more amino acids or nucleotides, requires a standalone ST.26 XML sequence listing.

Final Checklist for 2026 Compliance

Before submitting any patent application in 2026 involving biological sequences, verify the following:

Your sequence listing is saved as a valid ST.26 XML file
The file has been validated with WIPO Sequence software and shows zero errors
All sequences are correctly numbered starting from SEQ ID NO: 1
Organism names follow official taxonomic nomenclature
All mandatory qualifiers such as mol_type are present for every sequence
The file name follows the naming convention required by your target patent office
A copy of the ST.26 XML file has been submitted separately from the main application body

The st.26 sequence listing migration is not a one-time task. It is an ongoing operational change that affects every biotech or pharma patent filing going forward. Teams that invest in training, proper tooling, and updated internal workflows now will save significant time and avoid office actions and rejections in the months ahead.

Conclusion

The move from ST.25 to ST.26 represents a modern, globally harmonized approach to disclosing biological sequences in patent applications. While the technical learning curve exists, the st.26 sequence listing migration process becomes straightforward once you understand the tools, the rules, and the common pitfalls. Use this guide as your reference point, keep your WIPO Sequence software updated, and ensure every filing your team processes in 2026 meets the full ST.26 standard. Compliance is not optional, but with the right preparation, it is absolutely achievable.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.